Results 251 to 260 of about 53,113 (297)

No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with Bevacizumab. [PDF]

Liver Cancer
Jeschke M, Schütte JM, Himmen S, Herrmann K, Steinberg-Vorhoff HL, Theysohn JM, Best J, Schmidt HH, Jochheim LS.   +8 more
europepmc   +1 more source

Molecular Insights and Therapeutic Innovations in Cervical Cancer: Emerging Drug Targets

Advances in Pharmacological and Pharmaceutical Sciences, Volume 2026, Issue 1, 2026.
Cervical cancer is a significant global health challenge, ranking as the fourth most prevalent cancer among women worldwide. While human papillomavirus infection is the primary cause, the disease’s progression involves complex molecular mechanisms.
Abhijit Debnath, Rajesh Kumar Singh, Rupa Mazumder, Arpita Dua, Pankaj Kumar Tyagi, Anil Kumar Singh, Kuldeep Singh   +6 more
wiley   +1 more source

Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer. [PDF]

Transl Lung Cancer Res
May P, Winter C, Hubrecht I, Ortner E, Strathmeyer S, Geyer R, Heelemann S, Stratmann J, Schneller F, Bassermann F, Becker von Rose A.   +10 more
europepmc   +1 more source

Systematic Pathway Screening via Integrated Machine Learning Identifies FOXO‐Mediated Transcription Signature for Robust Immunotherapy Response Prediction in Non–Small Cell Lung Cancer

Human Mutation, Volume 2026, Issue 1, 2026.
Background Non–small cell lung cancer (NSCLC), accounting for 80% of lung cancer cases, remains a leading cause of cancer‐related mortality globally. While immune checkpoint inhibitors (ICIs) have improved outcomes, their efficacy is limited to a subset of patients, necessitating robust biomarkers for personalized immunotherapy response prediction ...
Shuqi Wu, Chenxi Deng, Chaofan Fan, Qiheng Liang, Lingxuan Zhu, Weiming Mou, Hongsen Huang, Keren Wu, Yizhang Li, Gengwen Deng, Liling Xu, Jiarui Xie, Chenglin Hong, Yuhang Deng, Xingjian Li, Changda Wu, Tao Yang, Peng Luo, Hank Z. H. Wong, Aimin Jiang, Anqi Lin, Xin Chen, Minghua Ren   +22 more
wiley   +1 more source

Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma [PDF]

Sang Youn Hwang, Hyun Young Woo, Jeong Heo, Hyung Jun Kim, Young Joo Park, Ki Youn Yi, Yu Rim Lee, Soo Young Park, Woo Jin Chung, Byoung Kuk Jang, Won Young Tak   +10 more
openalex   +1 more source

Integrated Multiomics Analysis Reveals a Migrasome‐Related Signature for Prognosis and Immunotherapy Response in Lung Adenocarcinoma

Human Mutation, Volume 2026, Issue 1, 2026.
Background Migrasomes, a newly identified subtype of extracellular vesicles generated during cell migration, play crucial roles in tumor microenvironment modulation. However, their systematic characterization in lung adenocarcinoma (LUAD) remains unexplored.
Jiayu Zhou, Tianye Song, Nengzheng Wang, Ce Liang, Ming Jiang, Xu Zhang, Hong Gao, Qingqing Feng, Sujit Nair   +8 more
wiley   +1 more source

FDA approves lurbinectedin in combination with atezolizumab for extensive-stage small cell lung cancer. [PDF]

Oncoimmunology
Kepp O, Kroemer G.
europepmc   +1 more source

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence‐based expert consensus recommendations for optimal management.
Rana R. McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Andrea Apolo, Michael B. Atkins, Rick Bangs, Kathryn E. Beckermann, Joaquim Bellmunt, Stephanie A. Berg, Mehmet A. Bilen, David Braun, Maria I. Carlo, Jason Efstathiou, Matthew Galsky, Petros Grivas, Shilpa Gupta, Naomi Haas, A. Ari Hakimi, Hans Hammers, Daniel Y. C. Heng, Michelle Hirsch, Gopakumar Iyer, Eric Jonasch, Vadim S. Koshkin, Oleksandr Kryvenko, Bryan Lewis, Roger Li, Surena Matin, Benjamin Maughan, David F. McDermott, Bradley McGregor, Joshua Meeks, Matthew Milowsky, Robert Motzer, Andrea Necchi, Dan Petrylak, Sima Porten, Thomas Powles, Brian Rini, Brian Shuch, Arlene Siefker‐Radtke, Guru Sonpavde, S. Srikala Sridhar, Cristina Suarez, Chad Tang, Abhishek Tripathi, Michiel S. Van Der Heijden, Martin Voss, Wenxin Xu, Tian Zhang, Jonathan Rosenberg, Toni K. Choueiri   +53 more
wiley   +1 more source

Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer. [PDF]

Front Immunol
Huang Y, Xu Z, Bao L.
europepmc   +1 more source

Impact of Tumor Burden on Immune Checkpoint and Conventional Therapy Responses and Outcomes. [PDF]

Cancer Res Commun
Gowda P, Govindu SR, Hsiehchen D.
europepmc   +1 more source